Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxycodone controlled-release - Intellipharmaceutics

Next Previous
Drug Profile

Oxycodone controlled-release - Intellipharmaceutics

Alternative Names: Abuse deterrent oxycodone hydrochloride extended release tablets - Intellipharmaceutics; Abuse-resistant oxycodone - Intellipharmaceutics; Aximris XR; Oxycodone CR - Intellipharmaceutics; Oxycodone ER - Intellipharmaceutics; Oxycodone hydrochloride extended-release tablets - Intellipharmaceutics; Rexista oxycodone

Latest Information Update: 08 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intellipharmaceutics International
  • Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Pain

Most Recent Events

  • 02 Jul 2020 Intellipharmaceutics and Purdue Pharmaceuticals enter into a stipulated dismissal agreement to terminate the patent litigation in respect to NDA filing in USA
  • 28 May 2020 No recent reports of development identified for phase-I development in Pain(In volunteers) in Canada (PO, Tablet)
  • 16 Jan 2020 The Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the US FDA voted to not support the approval of oxycodone extended-release tablets for pain

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top